Isaac Mohar, Ph.D., DABT
Dr. Mohar is an expert in toxicology and immunology. He has over 15 years of experience in drug and chemical toxicology, tissue immunology, and reproductive biology. Before joining Gradient, Dr. Mohar conducted research aimed at developing a malaria vaccine and identifying the immunological basis of cancer and chronic viral infections. His primary responsibilities at Gradient include assisting clients with evaluation of immunological data, and conducting risk-based human health and chemical safety evaluations. He has authored or co-authored several articles and method chapters in the areas of reproductive genetics, toxicology, and immunology.
Data Evaluation and Assay Development: Aided in the development of new assays to better understand tumor immunology. Evaluated flow cytometry data to gauge immune responses to skin cancer treatments. Advanced the client’s research and development of skin cancer treatments.
Preclinical Drug Development: Developed, contracted, and monitored preclinical testing program for an investigational new drug (IND). Assisted in providing client with a strategy and milestones for an IND submission to the US Food and Drug Administration (US FDA).
Sensitization Hazard Assessment: Provided toxicological hazard evaluation of chemicals, such as those present in consumer products or the workplace, for the potential to cause skin or respiratory sensitization.
Immunotoxicity Hazard Assessments: Reviewed evidence for various chemicals to induce immunotoxicity and other immune-related diseases.
Hazard Assessment: Provided toxicological and ecological hazard assessment of chemicals for Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH) compliance. Identified and classified potential hazards according to the United Nations Globally Harmonized System of Classification and Labelling of Chemicals (GHS).
Weight-of-Evidence Review: Reviewed weight of evidence for ozone to cause asthma or allergic airway disease.
Gasper, MA; Hesseling, AC; Mohar, I; Myer, L; Azenkot, T; Passmore, JS; Hanekom, W; Cotton, MF; Crispe, IN; Sodora, DL; Jaspan, HB. 2017. “BCG vaccination induces HIV target cell activation in HIV-exposed infants in a randomized trial.” JCI Insight 2:e91963.
Brempelis, KJ; Yuen, SY; Schwarz, N; Mohar, I; Crispe, IN. 2017. “Central Role of the TIR domain-containing adaptor-inducing interferon- (TRIF) Adaptor Protein in Murine Sterile Liver Injury.” Hepatology. doi:10.1002/hep.29078.
Kyriakides, M; Maitre, L; Stamper, BD; Mohar, I; Kavanagh, TJ; Foster, J; Wilson, ID; Holmes, E; Nelson, SD; Coen, M. 2016. “Comparative metabonomic analysis of hepatotoxicity induced by acetaminophen and its less toxic meta-isomer.” Arch. Toxicol. 90:3073-3085.
Mohar, I; Brempelis, KJ; Murray, SA; Ebrahimkhani, MR; Crispe, IN. 2015. “Isolation of non-parenchymal cells from the mouse liver.” Methods Mol. Biol. 1325:3-17.
Murray, SA; Mohar, I; Miller, JL; Brempelis, KJ; Vaughan, AM; Kappe, SH; Crispe, IN. 2015. “CD40 is required for protective immunity against liver stage Plasmodium infection.” J. Immunol. 194:2268-2279.
Mohar, I; Stamper, BD; Rademacher, PM; White, CC; Nelson, SD; Kavanagh, TJ. 2014. “Acetaminophen-induced liver damage in mice is associated with gender-specific adduction of peroxiredoxin-6.” Redox Biol. 2:377-387.